Predictive effect of five hepatitis B virus markers on re-vaccination time of hepatitis B vaccine

Jia,Qiuhua; Yu,Fei; Zhou,Qi; Chen,Xiaoyan; Gu,Zhaoqi; Ma,Chunling

doi:10.3892/etm.2020.8859

Predictive effect of five hepatitis B virus markers on re-vaccination time of hepatitis B vaccine

Authors:
- Qiuhua Jia
- Fei Yu
- Qi Zhou
- Xiaoyan Chen
- Zhaoqi Gu
- Chunling Ma
View Affiliations

Affiliations: Department of Medical Test, Women and Children's Health Care Hospital of Linyi, Linyi, Shandong 276000, P.R. China, Department of Clinical Laboratory, Affiliated Hospital of Shandong Medical College, Linyi, Shandong 276000, P.R. China, Experimental Center of Molecular Biology, Shandong Medical College, Linyi, Shandong 276000, P.R. China
Published online on: June 10, 2020 https://doi.org/10.3892/etm.2020.8859
Pages: 1709-1715

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Examination of predictive effect of five hepatitis B virus (HBV) markers on the re-vaccination time of hepatitis B vaccine was assessed. A total of 3,243 patients examined by five HBV markers in Women and Children's Health Care Hospital of Linyi from January 2015 to December 2017 were selected as the subjects and analyzed retrospectively. According to the previous time of hepatitis B antibody vaccination, subjects were divided into three groups: Short-term group (previous time of hepatitis B vaccination <5 years, n=798); medium-term group (>5 years - ≤10 years, n=1,242); long‑term group (>10 years, n=1,203). The enzyme linked immunosorbent assay was used to qualitatively analyze the five HBV markers, and chemiluminescence immunoassay was used to quantitatively analyze the five HBV markers. Hepatitis B surface antigen (HBsAg) in the long-term group and the medium-term group was significantly lower than that in the short-term group (P<0.001). HBsAg, hepatitis B e antigen, hepatitis B e antibody, hepatitis B core antibody in the long-term group was significantly higher than that in the medium-term and short-term group (P<0.050). The hepatitis B surface antibody in the long-term group was significantly lower than that in the other two groups (P<0.050). According to the previous time of the hepatitis B antibody vaccination, the patients in the long-term group were subdivided into three groups: Group A (vaccination time: 10-13 years, n=420); group B (13-15 years, n=377) and group C (>15 years, n=406). Geometric mean titer in group A was significantly lower than that in the other two groups (P<0.050). In conclusion, the protective effect of hepatitis B antibody vaccine is satisfactory for 10 years after vaccination, and re-vaccination is recommended after more than 13 years of vaccination when the virus begins to increase significantly, in order to prevent the occurrence of hepatitis B.

View Figures

View References

1	Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al: Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int. 10:1–98. 2016.PubMed/NCBI View Article : Google Scholar
2	Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM and Murad MH: American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 63:261–283. 2016.PubMed/NCBI View Article : Google Scholar
3	Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, et al: Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 63:284–306. 2016.PubMed/NCBI View Article : Google Scholar
4	Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, Wu V, Wong A, Wang Y, Zhang X, et al: Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 15:132–136. 2017.PubMed/NCBI View Article : Google Scholar
5	Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Prokop LJ, Murad MH and Mohammed K: Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 63:319–333. 2016.PubMed/NCBI View Article : Google Scholar
6	Ye B, Liu X, Li X, Kong H, Tian L and Chen Y: T-cell exhaustion in chronic hepatitis B infection: Current knowledge and clinical significance. Cell Death Dis. 6(e1694)2015.PubMed/NCBI View Article : Google Scholar
7	Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, Toomey M, Townshend-Bulson L, Rudolph K, Bulkow L, et al: Antibody levels and protection after hepatitis B vaccine: Results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 214:16–22. 2016.PubMed/NCBI View Article : Google Scholar
8	Hernán MA, Jick SS, Olek MJ and Jick H: Recombinant hepatitis B vaccine and the risk of multiple sclerosis: A prospective study. Neurology. 63:838–842. 2004.PubMed/NCBI View Article : Google Scholar
9	Van Damme P: Long-term protection after hepatitis B vaccine. J Infect Dis. 214:1–3. 2016.PubMed/NCBI View Article : Google Scholar
10	Qiu Y, Guo L, Zhang S, Xu B, Gao Y, Hu Y, Hou J, Bai B, Shen H and Mao P: DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN. Drug Deliv. 23:2391–2398. 2016.PubMed/NCBI View Article : Google Scholar
11	Nelson NP, Easterbrook PJ and McMahon BJ: Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 20:607–628. 2016.PubMed/NCBI View Article : Google Scholar
12	Guirguis-Blake JM, Senger CA, Webber EM, Mularski RA and Whitlock EP: Screening for chronic obstructive pulmonary disease: Evidence report and systematic review for the US preventive services task force. JAMA. 315:1378–1393. 2016.PubMed/NCBI View Article : Google Scholar
13	Eichelberger MC, Couzens L, Gao Y, Levine M, Katz J, Wagner R, Thompson CI, Höschler K, Laurie K, Bai T, et al: ELLA study participants: Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity. Vaccine. 34:458–465. 2016.PubMed/NCBI View Article : Google Scholar
14	Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F and Tacke F: European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 67:370–398. 2017.PubMed/NCBI View Article : Google Scholar
15	Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen HL, Lampertico P, Lau D, Bornstein JD, et al: Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 64:773–780. 2016.PubMed/NCBI View Article : Google Scholar
16	Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, et al: GS-US-320-0108 Investigators: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 1:196–206. 2016.PubMed/NCBI View Article : Google Scholar
17	Roberts H, Kruszon-Moran D, Ly KN, Hughes E, Iqbal K, Jiles RB and Holmberg SD: Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology. 63:388–397. 2016.PubMed/NCBI View Article : Google Scholar
18	Paul S, Saxena A, Terrin N, Viveiros K, Balk EM and Wong JB: Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: A systematic review and meta-analysis. Ann Intern Med. 164:30–40. 2016.PubMed/NCBI View Article : Google Scholar
19	Decorsière A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, Livingston CM, Niu C, Fletcher SP, Hantz O, et al: Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature. 531:386–389. 2016.PubMed/NCBI View Article : Google Scholar
20	Lok AS, Pan CQ, Han SH, Trinh HN, Fessel WJ, Rodell T, Massetto B, Lin L, Gaggar A, Subramanian GM, et al: Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 65:509–516. 2016.PubMed/NCBI View Article : Google Scholar
21	Harris AM, Iqbal K, Schillie S, Britton J, Kainer MA, Tressler S and Vellozzi C: Increases in acute hepatitis B virus infections - Kentucky, Tennessee, and West Virginia, 2006-2013. MMWR Morb Mortal Wkly Rep. 65:47–50. 2016.PubMed/NCBI View Article : Google Scholar
22	Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK, Kowdley KV, Bzowej N, et al: Hepatitis B Research Network: Hepatitis B Virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology. 150:684–695.e5. 2016.PubMed/NCBI View Article : Google Scholar
23	Takayama H, Sato T, Ikeda F and Fujiki S: Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 46:489–491. 2016.PubMed/NCBI View Article : Google Scholar
24	Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Nishimura D, Goto H and Hirooka Y: A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: Hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol. 9:252–256. 2016.PubMed/NCBI View Article : Google Scholar
25	Xiang KH, Michailidis E, Ding H, Peng YQ, Su MZ, Li Y, Liu XE, Dao Thi VL, Wu XF, Schneider WM, et al: Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. J Hepatol. 66:288–296. 2017.PubMed/NCBI View Article : Google Scholar
26	Fries LF, Smith GE and Glenn GM: A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med. 369:2564–2566. 2013.PubMed/NCBI View Article : Google Scholar
27	Patel M, Glass RI, Jiang B, Santosham M, Lopman B and Parashar U: A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis. 208:284–294. 2013.PubMed/NCBI View Article : Google Scholar
28	van Assen S, Holvast A, Telgt DSC, Benne CA, de Haan A, Westra J, Kallenberg CG and Bijl M: Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clin Immunol. 136:228–235. 2010.PubMed/NCBI View Article : Google Scholar
29	Folaranmi T, Rubin L, Martin SW, Patel M and MacNeil JR: Centers for Disease Control (CDC). Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 64:608–612. 2015.PubMed/NCBI
30	Benoit A, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, McElhaney JE, Oostvogels L, van Esse GA and Gaglani M: Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A/H3N2 influenza disease. Open Forum Infect Dis 2: ofv067. doi: 10.1093/ofid/ofv067. eCollection 2015 Apr.
31	Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, Xu K, Ren J, Yao J, Li Y, et al: Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 6(27251)2016.PubMed/NCBI View Article : Google Scholar